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AbstrAct
over the past few decades, there has been significant 
and impressive progress in the understanding and 
management of rheumatic diseases. one of the key 
reasons for succeeding in making this progress has 
been the increasingly stronger partnership between 
physicians and patients, setting a milestone in patient 
care. in this viewpoint, we discuss the recent evolution 
of the physician–patient relationship over time in europe, 
reflecting on the ‘journey’ from behind the clinic walls 
through to clinical and research collaborations at national 
and international level and the birth of healthcare 
professional and ‘rheumatic’ patient organisations. the 
role of expert patients and patient advocates in clinical 
and scientific committees now represents a core part 
of the decision-making process. in more recent years 
and following the recognition that the young patients, 
physicians and academics have a voice and needs of their 
own, including the need to be educated and instructed, 
has encouraged the establishment of youth organisations, 
enabling change and innovation to take place at a uniquely 
different level.
Rheumatology has witnessed rapid advances 
over time; from more than 100 years back 
when aspirin was ‘the’ treatment, through 
to the mid-20th century when the effects 
of cortisone were first observed, to current 
times, where biological agents and small 
molecules are catching headlines in the news. 
But would such progress have been made 
without interested clinicians and researchers 
dedicating their lives to understanding mech-
anistic pathways and therapeutic targets? 
More importantly, would this have been 
achieved without determined patients who 
believed, trusted and accepted treatments 
given to them? The answer is probably no. 
Scientific intelligence and the increasingly 
stronger partnership between physicians and 
patients over time have undoubtedly played 
a crucial role in better understanding rheu-
matic and musculoskeletal diseases (RMDs) 
and their treatment. The congregation of 
physicians, on the one hand, and patients, on 
the other, working together in partnership as 
a single unit rather than as different entities, 
has set important milestones and allowed the 
specialty to progress to a different level.
Patients and Physicians working in 
PartnershiP
The relationship between patients and 
physicians has received attention since the 
Hippocratic times.1 It is undoubtedly a rela-
tionship that has changed and matured 
through the years, with almost a complete 
turnaround of role and attitude: the emphasis 
is now on the patient talking and the physi-
cian listening and understanding the needs of 
the patient; the physician giving opinion and 
information and the patient making choice 
together with the physician; the patient asking 
and the physician answering. The communi-
cation between physicians and patients in the 
majority of the communities has progressively 
evolved into an open dialogue, transforming 
patients from passive recipients of informa-
tion and instructions to active participants in 
the management of their disease. The shift 
towards more patient-centred healthcare 
has necessitated important changes in the 
infrastructure and the way healthcare is deliv-
ered. This is, not surprisingly, more suited 
and more appealing to our target popu-
lation of patients with chronic, rheumatic 
musculoskeletal diseases (RMDs) often in the 
setting of many other coexisting (comorbid) 
conditions. Interestingly in the most recent 
treatment guidelines for RMDs released by 
the European League Against Rheumatism 
(EULAR), one of the overarching princi-
ples is that treatment should be based on a 
shared-decision process between the patient 
and the physician.2 3 Patient empowerment 
through tailored education and information 
becomes therefore a crucial aspect of health-
care, which we strongly advocate. However, 
we recognise that although clinicians and 
health professionals are advised to educate 
patients and support them with informa-
tion about their disease, they have limited 
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guidance about how to do this and to communicate the 
evidence-based medicine in a way patients will under-
stand. In this aspect, and in close collaboration between 
physicians and patients, the EULAR set of recommen-
dations for education of patients with inflammatory 
arthritis4 are well-received, as are recent discussions 
focusing on translating all recommendations in a friendly 
patient language. We should not forget that communi-
cation between patients and doctors is critical not just 
in clinical practice, but also in clinical research. In fact, 
the two are deeply linked as one informs the other, espe-
cially as there is evidence that the patient and physician 
perspectives diverge. For instance, in the development 
of the Rheumatoid Arthritis Impact of Disease (RAID) 
index, patients considered that ‘coping’ needed to be 
taken into account and doctors were not so in favour of 
this. The psychometric properties of the RAID, which 
includes ‘coping’, are better than other doctor-derived 
indices more widely used, for example, the 28-joint 
count Disease Activity Score  (DAS28).5 Some groups 
even consider that probably the best strategy to achieve 
a comprehensive and valid definition of states in disease 
will be to concur in the same group of people experi-
ences and technical expertise, that is, recruiting doctors 
with RMDs to ‘translate’ the experience to doctors.6
Outcomes Measures in Rheumatology (OMERACT) 
is a forum in which patient–researcher relationship 
is incredibly enriching (https://www. omeract. org/ 
patient_ research_ partners. php). OMERACT is an inde-
pendent international think-tank and hands-on focused 
on outcome measures in rheumatology. The group, a 
mix of stakeholders, from doctors, researchers, agen-
cies, industry and patients, meets every 2 years and works 
on agreed processes and projects between meetings. 
Recognising that nobody knows how arthritis changes 
one’s life better than the people who have the condition, 
OMERACT has Patient Research Partners fully inte-
grated into each stage of the OMERACT process. The 
majority of the most influential patient representatives 
in rheumatology have attended at least one OMERACT 
meeting. We recognise that patient research partners 
(PRPs) have made an important contribution to clinical 
research, helping define important outcome measures, 
such as minimum clinically important difference, recog-
nising domains of concern, such as sleep and fatigue, and 
ensuring feasibility of assessments, such as in the tolera-
bility of MRI scanning times.7
However, there is also the other side to the coin and 
it may be perceived that the call for patient involvement 
is perhaps going a little too far, with risks to becoming 
counterproductive. How much the patient perspective 
can and should be incorporated in clinical and scientific 
decisions can be subject to debate. As an example, the 
definition of treatment success for a clinician is often 
based purely on achieving a remission or at least low 
disease activity score, whereas for the patient remission 
may be completely unrelated or only partially related 
to a score reflecting disease activity. Instead, other 
important aspects of disease may be of greater relevance 
to the patient when it comes to whether treatment has 
succeeded or failed: for example, improved sleep, ability 
to remain socially engaged and in employment may be 
what disease remission and treatment success means to 
them.8–13
We therefore observe with delight that regulatory 
authorities require the patient perspective to be taken 
into account. Aside from the inclusion of patient-re-
ported outcomes in trials, the introduction of the 
patient’s voice in the evaluation of medicines and the 
patient’s contribution in the assessment of benefit and 
risk of therapeutic approaches is required.14 15 Of all 
stakeholders, regulators are the ones most interested 
in patients being educated in the process of drug devel-
opment and applaud and support initiatives such as the 
European Patients Academy (http://www. eupati. eu) and 
initiatives that focus on bringing the patient closer to 
the centre of medicines development, authorisation and 
reimbursement processes in the European Union (EU). 
Finally, we recognise that this evolution in the physician–
patient relationship has bridged many gaps between the 
two parties, prompting patient and physician groups 
to come together and work collaboratively towards 
achieving common goals, and strengthening research in 
rheumatology.
the birth of healthcare Professional/Physician 
organisations
The first attempt to establish a worldwide group for the 
study and control of rheumatic diseases dates back to 
1913 but it sadly failed due to World War I intervening. 
In 1925 the International League Against Rheumatism 
(ILAR) was formed in Paris representing the first step 
towards the development of regional leagues, namely 
Pan-American League of Rheumatology Associations 
(PANLAR) in the Pan-American Region in 1943, EULAR 
in the European region in 1947, the Asia Pacific League 
of Associations for Rheumatology in 1963 and in 1989 the 
African League (AFLAR). At national level, the American 
Rheumatism Association was founded in 1925, in 1965 
renamed the American College of Rheumatology.
A unique feature of EULAR is its three pillars (medical 
doctors/scientists, health professionals and people with 
RMDs) representing a broad audience and ensuring that 
voices from all relevant stakeholders are heard.
At present, we realise that at national level each country 
under the EULAR umbrella pursues similar objectives 
through their individual rheumatology societies. In the 
majority of cases, these represent highly active communi-
ties of rheumatology clinicians and academics with links 
to patient organisations and health professional associ-
ations working together in several clinical and research 
domains relating to the specialty.
What has been a real credit to patients with RMDs 
across the globe was the formation of organisations to 
support programmes in less developed countries that aim 
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to enhance the practice and education of rheumatology. 
For example, ILAR has a focused mission of advancing 
rheumatology in countries with an exceptional need. 
ILAR projects have varied in their focus from recom-
mendations for treating rheumatic diseases to setting up 
specialist clinics in low-income, middle-income countries 
to web-based educational programmes aimed at patients 
with rheumatic disease.
the role of Patient organisations
The crucial role of the patients as service users in iden-
tifying areas of improvement in healthcare provision as 
well as the growing need to engage patients in initiatives 
to improve on clinical and academic fronts has been 
prominent over the past decade. As a result, patient 
organisations were gradually established across countries, 
many of which have rightly gained key roles within exec-
utive committees of healthcare professionals (figure 1). 
This way it has been possible to have the patient’s voice 
and perspective heard and taken into account. We enthu-
siastically support the pairing of patient and physician 
organisations as it inevitably helps identify key areas 
that need development and addressing for patients with 
RMDs (table 1).
Many national patient organisations produce news-
letters, patient guidebooks and organise meetings and 
gatherings bringing people together. As a consequence 
of their many roles, it is evident that patient organisations 
also raise the awareness about the burden of RMDs as well 
as the impact to the patients and provide information, 
support and education to the patients to empower them 
to self-manage their disease. The majority of these organ-
isations have their own website and are active on social 
media platforms such as Facebook and Twitter, reaching 
out to as many people as possible. Patient forums and 
online blogs are becoming more and more frequent and 
have provided platforms for people to openly communi-
cate, build communities, share experiences, exchange 
information and learn from each other. Although there 
are mixed views about the use of social media in this 
manner, this seems to be the way the future of rheu-
matology is progressing and embracing this is probably 
better than resisting it.
Even in small communities/countries, patients have 
had a strong presence, working in partnership with rheu-
matologists at national and international level to enforce 
national strategic plans, but also raise awareness and 
contribute to improving the future of patients with RMDs 
globally. EULAR had a strong influence in encouraging 
patient collaboration with professionals in research, 
producing recommendations for inclusion of patient 
representatives in scientific projects.16 17 PRPs are there-
fore highly recommended and are currently involved in 
all EULAR research initiatives.
The EULAR People with Arthritis and Rheumatism 
across Europe (PARE) standing committee (http://
www. eular. org/ pare. cfm), set up in 2008 to succeed the 
EULAR Social Leagues, actively engages national organ-
isations of people with RMDs across Europe-related 
initiatives focusing on improving quality of life in patients 
with these diseases.
Figure 1 People with Arthritis and Rheumatism organisations across Europe.
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Table 1 People with Arthritis and Rheumatism across Europe organisations 2015/2016
Map number Acronym Full name Country Year of foundation
Members (2016 
update)
1 Österreichische Rheumaliga Austria 1995
2 Reumanet vzw. Belgium (Flanders) 2011 5000
3 CLAIR Confédération de Lutte contre 
les Affections Inflammatoires 
Rhumatismales
Belgium (Wallonia) 2004 2500
4 BOPRD Bulgarian Organisation for 
Patients with Rheumatic 
Diseases
Bulgaria 2010 300
5 HRVATSKA Liga Protiv Reumatizma Croatia 1992 5500
6 CYPLAR Cyprus League Against 
Rheumatism
Cyprus 1984 4450
7 Revma Liga v CR Czech Republic 1991 460
8 Gigtforeningen Denmark 1936 78 800
9 ERL Eesti Reumaliit Estonia 1991 11 subassociations
10 Suomen Reumaliitto Ry Finland 1947 45 000
11
AFLAR
Association Française de 
Lutte Anti-Rhumatismale France 1928 6500
12 Deutsche Rheuma-Liga
Bundesverband e.V. Germany 1970 280 000
13
E.Λ.Ε.Α.Ν.Α.
Hellenic League Against 
Rheumatism Greece 1978
14 Magyar Reumabetegek 
Egyesülete Hungary 1998
15 Gigtarfélag Íslands Iceland 1976 5030
16 Arthritis Ireland Ireland 400
17
INBAR
Israeli Arthritis Foundation & 
Lupus Org Israel 1985 4000
18
ANMAR
Associazione Nazionale 
Malati Reumatici Italy 1985 12 000
19
LKLSSB
Latvijas Kaulu, locītavu un 
saistaudu slimnieku biedrība Latvia 1998 650
20 Lietuvos Artrito Asociacija Lithuania 1998 2000
21
NORA
Non-governmental 
Organisation for Rheumatism 
& Arthritis Macedonia 2008 1009
22
Malta-ARAM
Arthritis and Rheumatism 
Association Malta Malta 2007 380
23 Association for Helping 
Persons with Rheumatic 
Diseases Montenegro 2003 2150
24 National Association 
ReumaZorg Nederland Netherlands 2014
25 NRF Norsk Revmatikerforbund Norway 1951 34 000
26
REF
Ogolnopolska Federacja 
Stowarzyszen Reumatykow Poland 2000
27
LPCDR
Liga Portuguesa Contra as 
Doenças Reumáticas Portugal 1982 500
28 Liga Romana Contra 
Reumatismului
Romania 2002 650
Continued
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PARE is involved in a number of projects, aiming to 
develop strong networks of effective, user-led organisations 
of people with RMDs; to ensure the voice of people with 
RMDs is heard and has influence among decision makers 
within Europe; to create powerful alliances that will make 
a difference to the lives of these people and to raise the 
awareness for RMDs.18 19 Key PARE projects include the 
coordination of the World Arthritis Day (www. worldar-
thritisday. org) which aims to raise awareness of all forms of 
RMDs among the medical community, people with RMDs 
and the general public. Second, it organises the EULAR 
Annual European Conference of PARE which aims to 
inspire, educate and empower the National Patient Repre-
sentatives. PARE has established a European Network of 
Patient Research Partners in order to influence research 
from a patient perspective and participation in EULAR 
scientific projects.
Other similar organisations to PARE include AGORA 
(http://www. agora- platform. eu), an ‘umbrella platform’ 
representing patient organisations of people with RMDs 
in Southern Europe. Set up in 2011, with a motto of 
‘Together we can’, AGORA has been an inspirational 
community of patients working towards improving 
quality of life and building a better future for people with 
RMDs. Many patient organisations have just like PARE set 
up their own annual conferences with the primary goal 
of inspiring, motivating and educating patient represen-
tatives on RMDs.
The role of patient advocates has gained increasing 
attention over time, fostering partnerships not only 
between patients and their families/carers, but impor-
tantly also between healthcare professionals, bridging 
gaps in care and improving communication but also with 
policymakers in order to influence and to be involved in 
the health policy. PARE’s vision for people with RMDs 
to be able to live full and independent lives has been a 
strong influence for patient advocates coming forward. 
As a result, advocacy activities towards the EU have had 
an important influence by creating public and political 
interest in RMDs and in people suffering from these. 
Starting back in 2004 with a campaign called Alliance 
Against Arthritis and working together with all three 
pillars of EULAR (clinicians, heath professionals and 
patient representatives) PARE organises activities in Brus-
sels yearly, aiming to engage the policymakers raising 
awareness for RMDs and stressing the need to implement 
effective policies and strategies to tackle the RMDs. This 
has led to two written declarations on RMDs (2005 and 
2008) highlighting the importance of the EU and its 
Member States in recognising the socioeconomic impor-
tance and other consequences of RMDs across all ages and 
assigning them appropriate priority. The launch of the 
first Written Declaration in 2005, instigated by EULAR, 
was officially announced at a reception in the European 
Parliament in Strasbourg. Also an Interest group was 
established consisting of parliamentarians and meeting 
three times a year to discuss relevant issues to RMDs.
Furthermore, the Secretariat of the European Parlia-
ment Interest Group on RMDs (2009–2014) has been 
run by EULAR and EULAR participated in the Council 
Conclusions on ‘Innovative approaches for chronic 
diseases in public health and healthcare systems’ elabo-
ration in 2010. As a consequence, the document released 
in 2013 acknowledged RMD burden and recognised 
that consistent efforts should be invested in research 
and innovation in this field. Of note, the legislative texts 
of Horizon 2020, the EU framework programme for 
research and innovation running from 2014 to 2020, 
included RMDs among the relevant chronic diseases that 
Horizon 2020 should address. With an 80 billion EUR 
budget, Horizon 2020 will provide resources to foster 
high-quality research in—among others—rheumatology 
and increase our knowledge on these conditions eventu-
ally improving their management.
Map number Acronym Full name Country Year of foundation
Members (2016 
update)
29
N.A.D.E.G.D.A.
National Public Organisation 
of disabled people Russia 2006
30
ORS
The Association of Rheumatic 
Diseases Patients of the 
Republic of Serbia Serbia 2007 1400
31 Liga proti reumatizmu Slovakia 1990
32
DRS
Slovenian Rheumatism 
Association Slovenia 1983 1550
33 LIRE Liga Reumatológica Española Spain 1973
34 Reumatikerförbundet Sweden 1945 50 000
35 RLS Rheumaliga Schweiz Switzerland 1958
36 Türkiye Romatizma Dernegi Turkey 1977
37
ARMA
Arthritis and Musculoskeletal 
Alliance UK 1972
Table 1 Continued 
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Finally, the European Commission has just launched 
(May 2017) the EU Network on Rare Diseases (ERN) 
with a branch to represent Rare Connective Tissue and 
Musculoskeletal Diseases (ERN ReCONNECT). The 
latter is endorsed by EULAR and PARE and has a mission 
to develop a framework for the delivery of high-quality, 
innovative, sustainable and equitable standard of care 
and practice for better access to care of European patients 
with rare Connective Tissue Diseases (rCTDs). All patient 
associations representing rCTDs have been involved 
in this initiative. The three main thematic groups of 
diseases identified in the ERN ReCONNET include rare 
autoimmune, complex autoimmune and rare hereditary 
connective tissue and musculoskeletal diseases (http:// 
rd- connect. eu/ news/ european- commission- approves- 23- 
european- reference- networks).
Making the voice of the young heard
We supported in recent years the need to make the 
voice and perspective of young physicians and patients 
with RMDs heard at national and international level 
and this has finally led to the establishment of several 
youth groups. In 2009 the EMerging EULAR NETwork 
(EMEUNET; http:// emeunet. eular. org) was established 
with the aim of bringing young aspiring rheumatolo-
gists and academics together to work towards enhancing 
the quality of their own education and to foster collab-
orations among emerging rheumatologists in EULAR 
countries.20 To date, EMEUNET is the largest European 
young rheumatologist group engaging in a number of 
educational initiatives, many linked with larger organisa-
tions including EULAR. At national level, several trainee 
networks exist, many rapidly growing in numbers and 
having an active influence on the way training is deliv-
ered in their respective countries. Examples include the 
British Rheumatologists in Training network and the 
Italian Young Rheumatologists Group .
Similarly, from the patients’ side, the Young PARE 
group (http://www. youngpare. org), recently developed 
within EULAR PARE, has been working towards estab-
lishing and strengthening youth patient organisations in 
European countries. This move stemmed primarily from 
the appreciation that the needs and priorities of young 
compared with adult patients differ and recognising 
these needs and priorities is crucial in order to optimise 
the management and relationship of young people with 
physicians
future ProsPects and final thoughts
So to answer the question of whether there is value in 
physician–patient collaboration, we conclude that there 
can really only be one answer: a simple, but strong and 
loud ‘yes’. Such collaboration is undoubtedly necessary 
to reach the mutual goal of optimising patient care and 
clinical outcomes, education and self-management and 
we are delighted to see it happening at two levels: the 
young and the senior/more established groups.
The science and knowledge are necessary for moving 
forward in the medical world. However, the real source of 
strength and potential for change draws inspiration from 
our patients; many highly motivated and with unique 
personal attributes striving for quality in healthcare and 
supporting fellow patients and healthcare professionals. 
It is one thing recognising this, though, and another 
actively doing something about it. Undoubtedly ‘expert’ 
patients and patient advocates in clinical areas but also 
scientific committees to strengthen patient representa-
tion will remain central to the future of rheumatology.
New and provocative views centre on how the patient 
perspective could modulate the physician perspective. Physi-
cians tend to think that they can easily overtake the patient 
rule in research and in decisions, ‘we are all patients’.
In this regard, a final thought to learning environ-
ments could be a breeding ground for improving 
the patient–doctor relationship, and even more to 
normalise it. The EULAR School of Rheumatology ( 
eular. org →  school_ of_ rheumatology. cfm) has estab-
lished a specific task force and classroom with the 
aim of developing ideas on how to further involve 
the patient perspective in the teaching and learning 
of future professionals. This might even imply expert 
and trained patients teaching future young doctors 
and health professionals at university, making relations 
more balanced, letting aside paternalism and creating 
a more patient-centred atmosphere.
With these prospects, the future landscape of rheuma-
tology in Europe is certainly changing and, we believe, 
on the right track for achieving this important mission: 
to keep to the lowest limit the global burden of RMDs.
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